Journal of Clinical Oncology, Vol 21, Issue 19
(October), 2003: 3665-3675
© 2003 American Society for Clinical Oncology
Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients
Melina Verso,
Giancarlo Agnelli
From the Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy.
Address reprint requests to Melina Verso, MD, Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università di Perugia, Via Enrico dal Pozzo, 06123 Perugia, Italy; e-mail: agnellig{at}unipg.it.
Long-term central venous catheters (CVCs) have considerably improved the management of cancer patients because they facilitate chemotherapy, transfusions, parenteral nutrition, and blood sampling. However, the use of long-term CVCs, especially for chemotherapy, has been associated with the occurrence of upper-limb deep venous thrombosis (UL-DVT). The incidence of clinically overt UL-DVT related to CVCs has been reported to vary between 0.3% and 28.3%. The incidence of CVC-related UL-DVT screened by venography reportedly varies between 27% and 66%. The incidence of clinically overt pulmonary embolism (PE) in patients with CVC-related UL-DVT ranges from 15% to 25%, but an autopsy-proven PE rate of up to 50% has been reported. Vessel injury caused by the procedure of CVC insertion, venous stasis caused by the indwelling CVC, and cancer-related hypercoagulability are the main pathogenetic factors for CVC-related venous thromboembolism (VTE). Several studies have assessed the benefit of the prophylaxis of UL-DVT after CVC insertion in cancer patients. According to the results of these studies, prophylaxis with low molecular weight heparin or a low fixed dose of warfarin has been recently proposed. However, the limitations of the experimental design of the prophylactic studies do not allow definitive recommendations. The recommended therapy for UL-DVT associated with CVC is based on anticoagulant therapy with or without catheter removal. This review focuses on the epidemiology, pathogenesis, diagnosis, prevention, and treatment of VTE in cancer patients with long-term CVC.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. De Cicco, M. Matovic, L. Balestreri, A. Steffan, R. Pacenzia, M. Malafronte, D. Fantin, C. A. Bertuzzi, F. Fabiani, S. Morassut, et al.
Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies
Ann. Onc.,
December 1, 2009;
20(12):
1936 - 1942.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Khorana, M. B. Streiff, D. Farge, M. Mandala, P. Debourdeau, F. Cajfinger, M. Marty, A. Falanga, and G. H. Lyman
Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action
J. Clin. Oncol.,
October 10, 2009;
27(29):
4919 - 4926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Khorana and G. C. Connolly
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
J. Clin. Oncol.,
October 10, 2009;
27(29):
4839 - 4847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Shivakumar, D. R. Anderson, and S. Couban
Catheter-Associated Thrombosis in Patients With Malignancy
J. Clin. Oncol.,
October 10, 2009;
27(29):
4858 - 4864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Debourdeau, D. Kassab Chahmi, G. Le Gal, I. Kriegel, E. Desruennes, M.-C. Douard, I. Elalamy, G. Meyer, P. Mismetti, M. Pavic, et al.
2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group
Ann. Onc.,
September 1, 2009;
20(9):
1459 - 1471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Rosati, S. Cordio, R. Bordonaro, G. Caputo, G. Novello, G. Reggiardo, and L. Manzione
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study
Ann. Onc.,
August 27, 2009;
(2009)
mdp359v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Starling, S. Rao, D. Cunningham, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, and A. R. Norman
Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group
J. Clin. Oncol.,
August 10, 2009;
27(23):
3786 - 3793.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Biffi, F. Orsi, S. Pozzi, U. Pace, G. Bonomo, L. Monfardini, P. Della Vigna, N. Rotmensz, D. Radice, M. G. Zampino, et al.
Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial
Ann. Onc.,
May 1, 2009;
20(5):
935 - 940.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gallieni, M. Pittiruti, and R. Biffi
Vascular Access in Oncology Patients
CA Cancer J Clin,
November 1, 2008;
58(6):
323 - 346.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Paauw, H. Borders, N. Ingalls, S. Boomstra, S. Lambke, B. Fedeson, A. Goldsmith, and A. T. Davis
The Incidence of PICC Line-Associated Thrombosis With and Without the Use of Prophylactic Anticoagulants
JPEN J Parenter Enteral Nutr,
July 1, 2008;
32(4):
443 - 447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. F. Aykan and E. Idelevich
The role of UFT in advanced gastric cancer
Ann. Onc.,
June 1, 2008;
19(6):
1045 - 1052.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Haller, J. Cassidy, S. J. Clarke, D. Cunningham, E. Van Cutsem, P. M. Hoff, M. L. Rothenberg, L. B. Saltz, H.-J. Schmoll, C. Allegra, et al.
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
J. Clin. Oncol.,
May 1, 2008;
26(13):
2118 - 2123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Vescia, A. K. Baumgartner, V. R. Jacobs, M. Kiechle-Bahat, A. Rody, S. Loibl, and N. Harbeck
Management of venous port systems in oncology: a review of current evidence
Ann. Onc.,
January 1, 2008;
19(1):
9 - 15.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Fagnani, R Franchi, C Porta, P Pugliese, K Borgonovo, A Bertolini, M Duro, A Ardizzoia, V Filipazzi, L Isa, et al.
Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis
Ann. Onc.,
March 1, 2007;
18(3):
551 - 555.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. B. Michaud, J. P. Karpinski, K. L. Jones, and J. Espirito
Dietary supplements in patients with cancer: Risks and key concepts, part 1
Am. J. Health Syst. Pharm.,
February 15, 2007;
64(4):
369 - 381.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Journeycake and G. R. Buchanan
Catheter-Related Deep Venous Thrombosis and Other Catheter Complications in Children With Cancer
J. Clin. Oncol.,
October 1, 2006;
24(28):
4575 - 4580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Gaitini, N. Beck-Razi, N. Haim, and B. Brenner
Prevalence of Upper Extremity Deep Venous Thrombosis Diagnosed by Color Doppler Duplex Sonography in Cancer Patients With Central Venous Catheters.
J. Ultrasound Med.,
October 1, 2006;
25(10):
1297 - 1303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Y.Y. Lee, M. N. Levine, G. Butler, C. Webb, L. Costantini, C. Gu, and J. A. Julian
Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer
J. Clin. Oncol.,
March 20, 2006;
24(9):
1404 - 1408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Glynne-Jones, J. Dunst, and D. Sebag-Montefiore
The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
Ann. Onc.,
March 1, 2006;
17(3):
361 - 371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Kohne and G. Folprecht
On prejudice and facts and choices
Ann. Onc.,
February 1, 2006;
17(2):
185 - 187.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Karthaus, A. Kretzschmar, H. Kroning, M. Biakhov, D. Irwin, N. Marschner, C. Slabber, G. Fountzilas, A. Garin, N. G. F. Abecasis, et al.
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
Ann. Onc.,
February 1, 2006;
17(2):
289 - 296.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Twelves, S. Gollins, R. Grieve, and L. Samuel
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer
Ann. Onc.,
February 1, 2006;
17(2):
239 - 245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Krzywda and D. A. Andris
Twenty-five Years of Advances in Vascular Access: Bridging Research to Clinical Practice
Nutr Clin Pract,
December 1, 2005;
20(6):
597 - 606.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. T. Alexandrescu and P. H. Wiernik
Cutaneous Manifestations of a Catheter-Related Thrombus
Arch Dermatol,
August 1, 2005;
141(8):
1049 - 1049.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Verso, G. Agnelli, S. Bertoglio, F. C. Di Somma, F. Paoletti, W. Ageno, M. Bazzan, P. Parise, R. Quintavalla, E. Naglieri, et al.
Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients
J. Clin. Oncol.,
June 20, 2005;
23(18):
4057 - 4062.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Levine and A.K. Kakkar
Catheter-Associated Thrombosis: Thromboprophylaxis or Not?
J. Clin. Oncol.,
June 20, 2005;
23(18):
4006 - 4008.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Feliu, P. Escudero, F. Llosa, M. Bolanos, J.-M. Vicent, A. Yubero, J.-J. Sanz-Lacalle, R. Lopez, L. Lopez-Gomez, E. Casado, et al.
Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study
J. Clin. Oncol.,
May 1, 2005;
23(13):
3104 - 3111.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Falanga and L. Zacharski
Deep vein thrombosis in cancer: the scale of the problem and approaches to management
Ann. Onc.,
May 1, 2005;
16(5):
696 - 701.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. V. Joffe, N. Kucher, V. F. Tapson, S. Z. Goldhaber, and for the Deep Vein Thrombosis (DVT) FREE Steering C
Upper-Extremity Deep Vein Thrombosis: A Prospective Registry of 592 Patients
Circulation,
September 21, 2004;
110(12):
1605 - 1611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Monagle, A. Chan, P. Massicotte, E. Chalmers, and A. D. Michelson
Antithrombotic Therapy in Children*: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
645S - 687S.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|